Cognition and the Predictive Utility of Three Risk Scores in an Ethnically Diverse Sample.


Journal

Journal of Alzheimer's disease : JAD
ISSN: 1875-8908
Titre abrégé: J Alzheimers Dis
Pays: Netherlands
ID NLM: 9814863

Informations de publication

Date de publication:
2020
Historique:
pubmed: 12 5 2020
medline: 11 5 2021
entrez: 12 5 2020
Statut: ppublish

Résumé

Various factors, such as age, cardiovascular concerns, and lifestyle patterns, are associated with risk for cognitive decline and Alzheimer's disease (AD). Risk scores model predictive risk of developing a disease (e.g., dementia, stroke). Many of these scores have been primarily developed in largely non-Hispanic/Latino (non-H/L) White samples and little is known about their applicability in ethno-racially diverse populations. The primary aim was to examine the relationship between three established risk scores and cognitive performance. These relationships were compared across ethnic groups. We conducted a cross-sectional study with a multi-ethnic, rural-dwelling group of participants (Mage = 61.6±12.6 years, range: 40-96 years; 373F:168M; 39.7% H/L). The Cardiovascular Risk Factors, Aging and Dementia (CAIDE), Framingham Risk Score (FRS), and Washington Heights-Inwood Columbia Aging Project (WHICAP) score were calculated for each participant. All three scores were significantly associated with cognition in both H/L and non-H/L groups. In H/Ls, cognition was predicted by FRS: β= -0.08, p = 0.022; CAIDE: β= -0.08, p < 0.001; and WHICAP: β= -0.04, p < 0.001. In non-H/Ls, cognition was predicted by FRS: β= -0.11, p < 0.001; CAIDE: β= -0.14, p < 0.001; and WHICAP: β= -0.08, p < 0.001. The strength of this relationship differed between groups for FRS [t(246) = -4.61, p < 0.001] and CAIDE [t(420) = -3.20, p = 0.001], but not for WHICAP [t(384) = -1.03, p = 0.30], which already includes ethnicity in its calculation. These findings support the utility of these three risk scores in predicting cognition while underscoring the need to account for ethnicity. Moreover, our results highlight the importance of cardiovascular and other demographic factors in predicting cognitive outcomes.

Sections du résumé

BACKGROUND
Various factors, such as age, cardiovascular concerns, and lifestyle patterns, are associated with risk for cognitive decline and Alzheimer's disease (AD). Risk scores model predictive risk of developing a disease (e.g., dementia, stroke). Many of these scores have been primarily developed in largely non-Hispanic/Latino (non-H/L) White samples and little is known about their applicability in ethno-racially diverse populations.
OBJECTIVE
The primary aim was to examine the relationship between three established risk scores and cognitive performance. These relationships were compared across ethnic groups.
METHODS
We conducted a cross-sectional study with a multi-ethnic, rural-dwelling group of participants (Mage = 61.6±12.6 years, range: 40-96 years; 373F:168M; 39.7% H/L). The Cardiovascular Risk Factors, Aging and Dementia (CAIDE), Framingham Risk Score (FRS), and Washington Heights-Inwood Columbia Aging Project (WHICAP) score were calculated for each participant.
RESULTS
All three scores were significantly associated with cognition in both H/L and non-H/L groups. In H/Ls, cognition was predicted by FRS: β= -0.08, p = 0.022; CAIDE: β= -0.08, p < 0.001; and WHICAP: β= -0.04, p < 0.001. In non-H/Ls, cognition was predicted by FRS: β= -0.11, p < 0.001; CAIDE: β= -0.14, p < 0.001; and WHICAP: β= -0.08, p < 0.001. The strength of this relationship differed between groups for FRS [t(246) = -4.61, p < 0.001] and CAIDE [t(420) = -3.20, p = 0.001], but not for WHICAP [t(384) = -1.03, p = 0.30], which already includes ethnicity in its calculation.
CONCLUSION
These findings support the utility of these three risk scores in predicting cognition while underscoring the need to account for ethnicity. Moreover, our results highlight the importance of cardiovascular and other demographic factors in predicting cognitive outcomes.

Identifiants

pubmed: 32390625
pii: JAD191284
doi: 10.3233/JAD-191284
pmc: PMC8273928
mid: NIHMS1610954
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1049-1059

Subventions

Organisme : NIA NIH HHS
ID : R01 AG054073
Pays : United States

Références

JAMA. 1997 Oct 22-29;278(16):1349-56
pubmed: 9343467
JAMA Neurol. 2019 Mar 1;76(3):264-273
pubmed: 30615028
JAMA Neurol. 2016 Oct 1;73(10):1231-1237
pubmed: 27533593
Learn Mem. 2019 Jun 17;26(7):235-244
pubmed: 31209118
Neurobiol Aging. 2009 Aug;30(8):1177-83
pubmed: 18077061
J Neurol Neurosurg Psychiatry. 1998 May;64(5):588-94
pubmed: 9598672
J Clin Exp Neuropsychol. 1998 Jun;20(3):310-9
pubmed: 9845158
Lancet Neurol. 2006 Sep;5(9):735-41
pubmed: 16914401
J Public Health (Oxf). 2019 Jun 1;41(2):305-312
pubmed: 30020483
Neurology. 2018 Jul 17;91(3):e217-e226
pubmed: 29898969
J Intern Med. 2018 Jun;283(6):597-603
pubmed: 29411449
Neurology. 1993 Nov;43(11):2412-4
pubmed: 8232972
Alzheimers Dement. 2019 Jan;15(1):17-24
pubmed: 30243772
Int J Epidemiol. 2015 Dec;44(6):1800-13
pubmed: 26705418
Neurology. 2013 Apr 2;80(14):1300-6
pubmed: 23547265
J Alzheimers Dis. 2019;68(1):145-158
pubmed: 30775996
Am J Cardiol. 2004 Jul 1;94(1):20-4
pubmed: 15219502
Alzheimers Dement. 2008 Jul;4(4):305-9
pubmed: 18631983
Circulation. 1998 May 12;97(18):1837-47
pubmed: 9603539
Alzheimers Dement. 2018 Apr;14(4):535-562
pubmed: 29653606
Prev Sci. 2013 Aug;14(4):411-21
pubmed: 23319292
Lancet Neurol. 2006 Jan;5(1):87-96
pubmed: 16361026
Alzheimers Dement. 2019 Dec;15(12):1524-1532
pubmed: 31606368
Circulation. 2008 Feb 12;117(6):743-53
pubmed: 18212285
BMJ. 2003 Feb 1;326(7383):251-2
pubmed: 12560273
J Intern Med. 2006 Sep;260(3):211-23
pubmed: 16918818
J Am Geriatr Soc. 2016 Dec;64(12):e265-e269
pubmed: 27996114
Curr Cardiovasc Risk Rep. 2011 Oct;5(5):407-412
pubmed: 22199992
JAMA. 2012 Nov 7;308(17):1775-84
pubmed: 23117778
Biol Psychiatry. 2012 Aug 15;72(4):324-30
pubmed: 22425413
J Am Coll Cardiol. 2009 Dec 8;54(24):2303-11
pubmed: 19958966
Ann Neurol. 1995 Feb;37(2):254-9
pubmed: 7847867
J Neurol Neurosurg Psychiatry. 2015 Dec;86(12):1299-306
pubmed: 26294005
J Alzheimers Dis. 2017;58(4):979-992
pubmed: 28527211
J Health Popul Nutr. 2017 Nov 13;36(1):36
pubmed: 29132438
Diabetes Care. 2014 Apr;37(4):1009-15
pubmed: 24271192
Alzheimers Dement. 2016 Jun;12(6):733-48
pubmed: 27016693
J Am Geriatr Soc. 1992 Dec;40(12):1221-6
pubmed: 1447438
Int J Environ Res Public Health. 2011 Mar;8(3):861-74
pubmed: 21556183
Arch Clin Neuropsychol. 1999 Feb;14(2):167-77
pubmed: 14590600
Neurology. 2019 Dec 10;93(24):e2247-e2256
pubmed: 31722961
J Am Geriatr Soc. 2019 Apr;67(4):734-740
pubmed: 30584655
Arch Neurol. 2010 Jul;67(7):835-41
pubmed: 20625090
Alzheimers Dement. 2018 Nov;14(11):1416-1426
pubmed: 30177276
Neuroimage. 2019 Jan 15;185:521-533
pubmed: 30312808

Auteurs

Stephanie Torres (S)

Department of Psychology, University of Houston, Houston, TX, USA.

Angel Alexander (A)

Department of Psychology, University of Houston, Houston, TX, USA.

Sid O'Bryant (S)

Department of Pharmacology & Neuroscience, University of Northern Texas Health Science Center, Fort Worth, TX, USA.

Luis D Medina (LD)

Department of Psychology, University of Houston, Houston, TX, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH